Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccination for malignant melanoma: recent developments.

D Jäger1, E Jäger, A Knuth

  • 1II. Medizinische Klinik, Hämatologie-Onkologie, Krankenhaus Nordwest, Frankfurt am Main, Deutschland.

Oncology
|January 11, 2001
PubMed
Summary

Cancer immunotherapy shows promise using tumor-associated antigens to stimulate immune responses. Peptide vaccinations have led to tumor regression, suggesting a potential adjuvant treatment for high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

ESMO gastrointestinal oncology·2026
Same author

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

ESMO gastrointestinal oncology·2026
Same author

Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis.

ESMO real world data and digital oncology·2026
Same author

CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial.

ESMO open·2025
Same author

Probing the Shell Effects on Fission: The New Superheavy Nucleus ^{257}Sg.

Physical review letters·2025
Same author

Stepping into the Sea of Instability: The New Sub-μs Superheavy Nucleus ^{252}Rf.

Physical review letters·2025

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Tumor-associated antigens recognized by the immune system offer new avenues for cancer immunotherapy.
  • Several categories of cancer-associated antigens are identified as targets for CD8+ T cells, including cancer-testis antigens, melanocyte differentiation antigens, mutated antigens, overexpressed antigens, and viral antigens.

Purpose of the Study:

  • To investigate the potential of active immunotherapy using tumor-associated antigens for cancer treatment.
  • To evaluate the efficacy of peptide immunization in inducing specific immune responses and tumor regression.

Main Methods:

  • Clinical trials involving antigenic peptides to induce specific immunological responses in vivo.
  • Assessment of peptide-specific reactions using immunological and clinical parameters like delayed-type hypersensitivity (DTH), CD8+ T cell responses, autoimmune responses, and tumor regression.

Related Experiment Videos

  • Utilizing the spontaneous antibody responses to tumor-associated antigens (SEREX) strategy to identify new antigens like NY-ESO-1.

    • Main Results:

    • Intradermal vaccination with tumor-associated peptides alone elicited specific DTH and CD8+ T cell responses, correlating with tumor regression.
    • Complete tumor regressions were observed following the induction of CD8+ T cell responses via peptide immunization.
    • The SEREX strategy identified NY-ESO-1, with NY-ESO-1-specific immune responses found in about 50% of patients with NY-ESO-1-positive tumors.

    Conclusions:

    • Active immunotherapy with tumor-associated antigens presents a promising approach for adjuvant cancer treatment in patients at high risk of recurrence.
    • Peptide immunization can effectively induce CD8+ T cell responses, leading to significant tumor regression.
    • Further clinical studies are underway to assess the immunological effects of NY-ESO-1 peptide immunization in cancer patients.